Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 329 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06058078RecruitingPhase 2
Cell therapy for active lupus nephritis
This trial tests a new cell therapy (RY_SW01) for people with active lupus nephritis (kidney inflammation caused by lupus) who haven't responded well to standard treatments. It aims to see if the therapy can help control the disease.
Nanjing, JiangsuAges 18–65 - NCT06032923RecruitingPhase 1/Phase 2
Does vitamin B3 boost help lupus symptoms?
This study tests whether a form of vitamin B3, called nicotinamide riboside, can improve immune function and reduce inflammation in women with mild to moderate lupus. It may help understand if boosting NAD+ levels offers a new way to manage the disease.
Bethesda, MarylandAges 18–120 - NCT06010472RecruitingEarly Phase 1
Car-NK cell therapy for lupus
This trial tests a new immune cell therapy (CAR NK cells) for people with moderate to severe lupus that hasn't responded well to standard treatments. The therapy targets a protein called CD19 on certain immune cells to calm the overactive immune system.
ShanghaiAges 18–65 - NCT05927688Recruiting
Using patient reports to adjust treatment for autoimmune diseases
This study looks at whether doctors consider patient “electronic reports” (completed online/phone) when deciding how often to change treatment. It may help improve how well treatment plans match how patients feel over time.
StrasbourgAges 18 years+ - NCT05835310RecruitingPhase 3
IV anifrolumab for active lupus in children
This study tests whether an intravenous medicine called anifrolumab can safely improve active systemic lupus (SLE) in children. If you qualify, you may receive the study treatment and be closely monitored for safety and lupus symptoms.
Phoenix, ArizonaAges 5–17 - NCT05799378RecruitingPhase 3
Stopping hydroxychloroquine in older adults with stable lupus
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
Los Angeles, CaliforniaAges 55 years+ - NCT07509892RecruitingPhase 2
Testing TQH3906 for people with active lupus
This study tests a new medicine, TQH3906, in people with systemic lupus erythematosus (SLE) who have moderate to severe disease activity. It aims to see if TQH3906 can safely reduce lupus symptoms like joint pain, skin rash, or vasculitis.
Bengbu, AnhuiAges 18–74 - NCT05698173Recruiting
Study of lupus and accelerated aging
This study looks at how lupus relates to “accelerated aging” and may help researchers better understand disease effects over time. You might be able to join if you have systemic lupus and are able to consent and participate.
BordeauxAges 18–60 - NCT07691970RecruitingPhase 3
Continued treatment study for people who benefited from anifrolumab
This study lets people who finished a previous anifrolumab (Saphnelo) trial and saw benefits continue getting the treatment. It aims to see how well the drug works over a longer time.
Phoenix, ArizonaAges 5–80 - NCT05559671RecruitingPhase 4
Shingles vaccine safety study for people with lupus
This Phase 4 study checks how safe a shingles vaccine (Shingrix, a non-live vaccine) is for adults with lupus. You might be invited if you have lupus and haven’t had certain shingles or chickenpox-related vaccines recently, and if your lupus symptoms and immune health meet the study rules.
New York, New YorkAges 18–90 - NCT05538208RecruitingPhase 2
Children with lupus kidney inflammation using mycophenolate
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
San Francisco, CaliforniaAges 8–20 - NCT05440422RecruitingPhase 2
Anifrolumab for heart health in lupus patients
This study tests whether anifrolumab, a drug that targets the immune system, can improve markers of blood vessel health in people with lupus. It may help reduce the risk of heart problems associated with lupus.
Bethesda, MarylandAges 18–80 - NCT05443516Recruiting
Blood and urine markers in active lupus kidney disease
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
BrusselsAges 18–70 - NCT05394922Recruiting
Study of sugar patterns in lupus anti-DNA antibodies
This study looks at the “sugar coating” on anti-DNA antibodies in people with lupus. The goal is to better understand these antibody patterns, which may help improve how lupus is studied or treated in the future.
MontpellierAges 18–80 - NCT07700940RecruitingPhase 4
Empagliflozin for kidney function in lupus nephritis
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
Banī SuwayfAges 18–65 - NCT05352919Enrolling by invitationPhase 3
Long-term study of litifilimab for lupus symptom control
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
Phoenix, ArizonaAges 18 years+ - NCT05268289RecruitingPhase 2
Trial for lupus kidney inflammation using LNP023
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Phoenix, ArizonaAges 18–100 - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
La Jolla, CaliforniaAges 18 years+ - NCT05207358RecruitingPhase 4
Lower steroid use in active lupus kidney inflammation
This trial looks at whether people with proliferative lupus nephritis can use less steroid medicine while still controlling kidney inflammation. It may help reduce steroid side effects, while testing a carefully monitored treatment plan.
BucharestAges 18–80 - NCT05097365Enrolling by invitation
Testing a methyl-donor supplement to study lupus metabolism
This study looks at whether a “methyl-donor” nutrient supplement changes metabolism (methylation) in people with lupus who are also in the childbearing age range and have low-to-moderate disease activity. It may help researchers understand why lupus acts differently in some people and how diet-related pathways could affect symptoms.
São PauloAges 18–45 - NCT05039619RecruitingPhase 2
Obinutuzumab trial for adolescents with active lupus kidney inflammation
This Phase 2 study tests obinutuzumab, a targeted antibody medicine, in teens with active lupus nephritis (inflammation in the kidney). It looks at whether it helps kidney disease and is safe, including how the body handles the drug.
Loma Linda, CaliforniaAges 5–17 - NCT05018858RecruitingPhase 1
Test stem cell infusion safety for lupus
This early-phase study tests whether an intravenous (through a vein) stem cell treatment made from donated umbilical cord tissue is safe for people with lupus. It focuses mainly on side effects and how well participants tolerate the infusion.
St John'sAges Any age - NCT07713940Recruiting
Anti-inflammatory diet study for lupus patients
This study tests whether an anti-inflammatory diet can help people with lupus who are on certain medications. It focuses on reducing pain and improving quality of life over 12 weeks.
La Jolla, CaliforniaAges 18 years+ - NCT04976322Enrolling by invitationPhase 3
Long-term lupus treatment safety study with dapirolizumab
This Phase 3 study tests whether dapirolizumab pegol is safe and tolerable for people with systemic lupus erythematosus (SLE) when taken long-term. You may be offered a chance to stay on this medicine if the study team thinks you could benefit.
Birmingham, AlabamaAges 16 years+
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 329 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.